NCCN guidelines indicate rusfertide for patients who are intolerant to phlebotomy or who receive frequent phlebotomy, regardless of risk status.
|Videos|October 18, 2016
Harry Erba, MD, PhD, provides information on the diagnosis and treatment of patients with polycythemia vera: Case 1
Harry Erba, MD, PhD, provides information on the diagnosis and treatment of patients with polycythemia vera
Advertisement
A Patient with Disease Progression on Hydroxyurea
Case 1:
Advertisement
Related to this article
The FDA designation is for LYT-200 plus a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.
The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
IMS Day 1 Recap: Bispecific and CAR T Data Shape Myeloma Treatment
2
What to Watch at IMS 2026: Defining Cure as Multitargeting, CELMoDs, and In Vivo CAR T Move Forward
3
Tovecimig Submission for Biliary Tract Cancer Is Proceeding Despite FDA Request for New Trial
4
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
5